References of "Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPlasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Fernández de Larrea, C; Kyle, RA; Durie, BG et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2013), 27(4), 780-91

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailImpact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia : a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation
Baron, Frédéric ULg; Labopin, M.; Niederwieser, D. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2012), 26(12), 2462-2468

This report investigated the impact of graft-versus-host disease (GVHD) on transplantation outcomes in 1859 acute myeloid leukemia patients given allogeneic peripheral blood stem cells after reduced ... [more ▼]

This report investigated the impact of graft-versus-host disease (GVHD) on transplantation outcomes in 1859 acute myeloid leukemia patients given allogeneic peripheral blood stem cells after reduced-intensity conditioning (RIC allo-SCT). Grade I acute GVHD was associated with a lower risk of relapse (hazards ratio (HR)¼0.7, P¼0.02) translating into a trend for better overall survival (OS; HR¼1.3; P¼0.07). Grade II acute GVHD had no net impact on OS, while grade III–IV acute GVHD was associated with a worse OS (HR¼0.4, Po0.0.001) owing to high risk of nonrelapse mortality (NRM; HR¼5.2, Po0.0001). In time-dependent multivariate Cox analyses, limited chronic GVHD tended to be associated with a lower risk of relapse (HR¼0.72; P¼0.07) translating into a better OS (HR¼1.8; Po0.001), while extensive chronic GVHD was associated with a lower risk of relapse (HR¼0.65; P¼0.02) but also with higher NRM (HR¼3.5; Po0.001) and thus had no net impact on OS. In-vivo T-cell depletion with antithymocyte globulin (ATG) or alemtuzumab was successful at preventing extensive chronic GVHD (Po0.001), but without improving OS for ATG and even with worsening OS for alemtuzumab (HR¼0.65; P¼0.001). These results highlight the role of the immune-mediated graft-versus-leukemia effect in the RIC allo-SCT setting, but also the need for improving the prevention and treatment of severe GVHD. [less ▲]

Detailed reference viewed: 23 (5 ULg)
Full Text
Peer Reviewed
See detailUnrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia : a survey on behalf of Eurocord and CLWP of EBMT
Robin, M.; Sanz, G. F.; Ionescu, I. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2011), 25

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detailSHIP-1 inhibits CD95/APO-1/Fas-induced apoptosis in primary T lymphocytes and T leukemic cells by promoting CD95 glycosylation independently of its phosphatase activity
Charlier, Edith ULg; Condé, Claude ULg; Zhang, Jing et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2010)

SHIP-1 functions as a negative regulator of immune responses by hydrolyzing phosphatidylinositol-3,4,5-triphosphate generated by PI 3-kinase activity. As a result, SHIP-1 deficiency in mice results in ... [more ▼]

SHIP-1 functions as a negative regulator of immune responses by hydrolyzing phosphatidylinositol-3,4,5-triphosphate generated by PI 3-kinase activity. As a result, SHIP-1 deficiency in mice results in myeloproliferation and B cell lymphoma. On the other hand, SHIP-1 deficient mice have a reduced T cell population, but the underlying mechanisms are unknown. In this work, we hypothesized that SHIP-1 plays anti-apoptotic functions in T cells upon stimulation of the death receptor CD95/APO-1/Fas. Using primary T cells from SHIP-1-/- mice and T leukemic cell lines, we report here that SHIP-1 is a potent inhibitor of CD95-induced death. We observed that a small fraction of the SHIP-1 pool is localized to the endoplasmic reticulum where it promotes CD95 glycosylation. This post-translational modification requires an intact SH2 domain of SHIP-1, but is independent of its phosphatase activity. The glycosylated CD95 fails to oligomerize upon stimulation, resulting in impaired DISC formation and downstream apoptotic cascade. These results uncover an unanticipated inhibitory function for SHIP-1 and emphasize the role of glycosylation in the regulation of CD95 signaling in T cells. This work may also provide a new basis for therapeutic strategies using compounds inducing apoptosis through the CD95 pathway on SHIP-1 negative leukemic T cells. [less ▲]

Detailed reference viewed: 79 (16 ULg)
Full Text
Peer Reviewed
See detailKIR-ligand incompatibility in the Graft-versus-host direction improves outcome after umbilical cord blood transplantation for acute leukemia
Willemze, R.; Rodrigues, C. A.; Labopin, M. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2009), 23

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailNon-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial.
Willems, Evelyne ULg; Baron, Frédéric ULg; Baudoux, Etienne ULg et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2009), 23(3), 608-10

Detailed reference viewed: 76 (38 ULg)
Full Text
Peer Reviewed
See detailHyperdiploid karyotypes in acute myeloid leukemia define a novel entity : a study of 38 patients from the Groupe Francophone de Cytogenetique Hematologique (GFCH)
Luquet, I.; Laï, J. L.; Barin, C. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2008), 22(1), 132-137

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailAcute myeloid leukaemia with 8p11 (MYST3) rearrangement : an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique
Gervais, C.; Murati, A.; Helias, C. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2008), 22(8), 1567-1575

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailNeighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells
CAERS, Jo ULg; Deleu, Sara; Belaid, Zakia et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2007), 21(7), 1580-4

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailHuman erythroleukemia: is the two-hit model of mouse leukemogenesis valid in human disease?
Coulon, Séverine; Vandekerckhove, Julie; Dussiot, Michael et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2007)

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailNon-infusional vs intravenous consolidation chemotherapy in eldery patients with acute myeloid leukemia : final results of th EORTC-GIMAMA AML-13 randomized phase III trial
Jehn, U.; Suciu, S.; Thomas, X. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2006), 20

Detailed reference viewed: 26 (4 ULg)
Full Text
Peer Reviewed
See detailEndothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.
De Bruyne, Elke; Andersen, T. L.; De Raeve, Hendrik et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2006), 20(10), 1870-9

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailTransfusions after nonmyeloablative or reduced-intensity conditioning regimens.
Baron, Frédéric ULg; Vanstraelen, Gaëtan; Beguin, Yves ULg

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2006), 20(12), 2081-6

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailAssociation of acute leukemia and autoimmune polyendocrine syndrome in two kindreds.
Willems, Evelyne ULg; Valdes Socin, Hernan Gonzalo ULg; Betea, Daniela ULg et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2003), 17(9), 1912-1914

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailRemission of severe cold agglutinin disease after Rituximab therapy.
LAYIOS, Nathalie ULg; Van Den Neste, E.; Jost, E. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2001), 15(1), 187-8

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailEstimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters.
Bowen, D. T.; Culligan, D.; Beguin, Yves ULg et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (1994), 8(1), 151-5

The erythroid abnormality in patients with myelodysplasia (MDS) is multifactorial, with ineffective erythropoiesis and poor in vitro progenitor response to erythropoietin (EPO). Serum EPO concentration is ... [more ▼]

The erythroid abnormality in patients with myelodysplasia (MDS) is multifactorial, with ineffective erythropoiesis and poor in vitro progenitor response to erythropoietin (EPO). Serum EPO concentration is variable among patients for a given haemoglobin concentration. We studied 19 non-transfusion-dependent patients with MDS, and 13 healthy elderly control subjects in an attempt to define the factors governing variability in serum EPO and to further characterise the anaemia of MDS. Serum EPO concentration was appropriate for the degree of anaemia in 15/19 MDS patients, and was positively related to mean cell volume (MCV), mean cell haemoglobin (MCH), and percentage highly fluorescent reticulocytes (% HFR), but not to absolute or percentage reticulocyte count. Although the observed/predicted ratio for serum transferrin receptor (TfR) concentration was low in 12 of 19 MDS subjects, no relationship to haemoglobin concentration, reticulocytes or serum EPO was seen. Serum TfR was positively correlated with WBC and platelet counts. Serum TfR was higher in patients with sideroblastic anaemia than refractory anaemia. Standardized in vivo p50 was positively correlated to red cell 2,3 diphosphoglycerate concentration, although this was not the only factor influencing the oxygen dissociation curve. We conclude that effective erythroid output responsive to endogenous EPO drive in MDS is positively related to MCV, MCH and % HFR. Serum TfR may not represent effective output as precisely as % HFR, but may be proportional to total marrow erythropoietic activity. [less ▲]

Detailed reference viewed: 37 (1 ULg)
Peer Reviewed
See detailMixed Phenotype Murine Leukemias
Defresne, Marie-Paule ULg; Borremans, B.; Verhofstede, C. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (1993), 7(8), 1253-60

Cell lines were derived from eight individual leukemias induced by X-rays in NFS mice. First typed as null cells (surface immunoglobulin negative, Thy-1 negative), they turned out to have a mixed ... [more ▼]

Cell lines were derived from eight individual leukemias induced by X-rays in NFS mice. First typed as null cells (surface immunoglobulin negative, Thy-1 negative), they turned out to have a mixed phenotype with myeloid cytochemical markers, pre-B surface antigens and molecular markers of pro-B lymphocytes. They represent murine models for mixed phenotype (pro-pre-B-myeloid) leukemias. [less ▲]

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailSoluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin, Yves ULg; Lampertz, S.; De Groote, D. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (1993), 7(12), 2019-2025

We measured the soluble (s) receptors CD23, CD8, CD4, interleukin-2 receptor (IL-2R, CD25), and transferrin receptor (TfR, CD71), in normal serum and in patients with chronic lymphocytic leukemia (CLL ... [more ▼]

We measured the soluble (s) receptors CD23, CD8, CD4, interleukin-2 receptor (IL-2R, CD25), and transferrin receptor (TfR, CD71), in normal serum and in patients with chronic lymphocytic leukemia (CLL) and evaluated them in relation to clinical and biological parameters of the disease, as well as serum immunoglobulin E (IgE). Compared to 31 normal individuals, 42 CLL patients had increased levels of sCD23 (98.4 +/- 127.7 versus 0.9 +/- 0.3 U/ml, p < 0.001), sIL-2R (6080 +/- 7030 versus 1420 +/- 640 pg/ml, p < 0.001), sTfR (12,100 +/- 11,250 versus 5000 +/- 1050 ng/ml, p < 0.001), and sCD8 (510 +/- 191 versus 234 +/- 89 U/ml, p < 0.001), but normal sCD4 levels. Mean sCD23 levels remained normal in patients with non-Hodgkin's lymphoma (other than small lymphocytic), Hodgkin's disease, hairy cell leukemia, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), multiple myeloma, or solid tumors. Advancing Rai clinical stage was associated with a progressive elevation of sCD23 (p < 0.001), while sCD8 (p < 0.05), sIL-2R (p < 0.001), and sTfR (p < 0.005) were highest in stage 2 patients. Discriminant analysis confirmed the value of soluble receptor determinations in the clinical evaluation of CLL patients. sCD23 correlated with sIL-2R (p < 0.001) and sTfR (p < 0.05) but not with sCD4 or sCD8, and displayed an inverse relationship with serum IgE (NS) and total gamma-globulin (p < 0.05). sIL-2R correlated with sCD23 (p < 0.001), sTfR (p < 0.001), sCD4 (p < 0.01), and sCD8 (p < 0.01). The lymphocyte count correlated with serum lactate dehydrogenase (LDH) (p < 0.05), sCD23 (p < 0.001) and sIL-2R (p < 0.01) but not sTfR, sCD8, or sCD4. Chemotherapy produced consistent reductions of sCD23 levels in two responding patients. We conclude that: (i) sCD23 is considerably elevated in CLL, correlates with the tumor mass and clinical stage, and could be helpful in monitoring these patients; and (ii) sIL-2R, sCD8, and sTfR levels are less specifically increased and could be influenced by other factors such as immune activation and erythropoiesis. [less ▲]

Detailed reference viewed: 89 (3 ULg)
Peer Reviewed
See detailTnf-Alpha and Radiation-Induced Thymic Lymphomas
Boniver, Jacques ULg; Humblet, Chantal ULg; Delvenne, Philippe ULg et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (1992), 6(Suppl 3), 83-84

Detailed reference viewed: 5 (2 ULg)